A retrospective study: Factors associated with the risk of abdominal aortic aneurysm rupture

Vascular Pharmacology

Volumn 65, Issue , 2015, Pages 13-16

  Gokani, V J ^a   Sidloff, D ^a   Bath, M F ^a   Bown, M J ^a   Sayers, R D ^a   Choke, E ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

AAA rupture risk; Risk factor; Statin therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL AORTA ANEURYSM; AGED; AGING; ANEURYSM RUPTURE; ANEURYSM SURGERY; ARTICLE; FEMALE; GENDER; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; ADVERSE EFFECTS; AGE; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; COMPLICATION; ELECTIVE SURGERY; EMERGENCY TREATMENT; FACTUAL DATABASE; PROCEDURES; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; VASCULAR SURGERY;

AGE FACTORS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; DATABASES, FACTUAL; ELECTIVE SURGICAL PROCEDURES; EMERGENCY TREATMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; VASCULAR SURGICAL PROCEDURES;

EID: 84924591565     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.11.006     Document Type: Article

References (27)

1. Office of National Statistics Mortality statistics: deaths registered in England and Wales (Series DR), 2011 2011, HMSO, London.
2. Baxter B.T., Terrin M.C., Dalman R.L. Medical management of small abdominal aortic aneurysms. Circulation 2008, 8;117(14):1883-1889.
3. Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA)-a systematic review. EJVES 2011, 41:663-667.
4. Rughani G., Robertson L., Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev 2012, 12(9):CD009536.
5. Takagi H., Yamamoto H., Iwata K., Goto S., Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. EJVES 2012, 44(3):287-292. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group.
6. Mastoraki S.T., Toumpoulis I.K., Anagnostopoulos C.E., Tiniakos D., Papalois A., Chamogeorgakis T.P., Rokkas C.K., et al. Treatment with simvastatin inhibits the formation of abdominal aortic aneurysms in rabbits. Ann Vasc Surg 2012, 26(2):250-258.
7. Brady A.R., Thompson S.G., Fowkes F.G., Greenhalgh R.M., Powell J.T. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004, 110:16-21.
8. Lindholt J.S., Heegaard N.H., Vammen S., Fasting H., Henneberg E.W., Heickendorff L. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. EJVES 2001, 21:51-56.
9. Vainas T., Lubbers T., Stassen F.R., Herngreen S.B., van Dieijen-Visser M.P., Bruggeman C.A., et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003, 107(8):1103-1105.
10. Middleton R.K., Lloyd G.M., Bown M.J., Cooper N.J., London N.J., Sayers R.D. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007, 45(3):574-580.
11. Piechota-Polanczyk A., Goraca A., Demyanets S., Mittlboeck M., Domenig C., Neumayer C., et al. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-κB. EJVES 2012, 44(2):133-137.
12. Xu C., Zarins C.K., Glagov S. Aneurysmal and occlusive atherosclerosis of the human abdominal aorta. J Vasc Surg 2001, 33:91-96.
13. Wilson W.R., Evans J., Bell P.R., Thompson M.M. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. EJVES 2005, 30(3):259-262.
14. Periard D., Guessous I., Mazzolai L., Haesler E., Monney P., Hayoz D. Reduction of small infrarenal abdominal aortic aneurysm expansion rate by statins. Vasa 2012, 41(1):35-42.
15. Kalyanasundaram A., Elmore J.R., Manazer J.R., Golden A., Franklin D.P., Galt S.W., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006, 43(1):117-124.
16. EVAR Trial Participants Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet 2005, 365:2187-2192.
17. Erbel R., Aboyans V., Boileau C., Bossone E., Di Bartolomeo R., Eggebrecht H., et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014, 35(41):2873-2926.
18. Zhang H., Plutzky J., Skentzos S., Morrison F., Mar P., Shubina M., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013, 158(7):526-534.
19. Brown L.C., Powell J.T. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. Ann Surg 1999, 230(3):289-296.
20. Cronenwett J.L., Sargent S.K., Wall M.H., Hawkes M.L., Freeman D.H., Dain B.J., et al. Variables that affect the expansion rate and outcome of small abdominal aortic aneurysms. J Vasc Surg 1990, 11:260-269.
21. Sweeting M.J., Thompson S.G., Brown L.C., Powell J.T. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012, 99:655-665. RESCAN collaborators.
22. Brown P.M., Zelt D.T., Sobolev B. The risk of rupture in untreated aneurysms: the impact of size, gender, and expansion rate. J Vasc Surg 2003, 37(2):280-284.
23. Powell J.T., Brown L.C., Greenhalgh R.M., Thompson S.G. The rupture rate of large abdominal aortic aneurysms: is this modified by anatomical suitability for endovascular repair?. Ann Surg 2008, 247(1):173-179.
24. Haque M., Francis J., Sehgal I. Aryl hydrocarbon exposure induces expression of MMP-9 in human prostate cancer cell lines. Cancer Lett 2005, 225(1):159-166.
25. Pei X.H., Nakanishi Y., Inoue H., Takayama K., Bai F., Hara N. Polycyclic aromatic hydrocarbons induce IL-8 expression through nuclear factor kappaB activation in A549 cell line. Cytokine 2002, 19(5):236-241.
26. Curfs D.M., Lutgens E., Gijbels M.J., Kockx M.M., Daemen M.J., van Schooten F.J. Chronic exposure to the carcinogenic compound benzo[a]pyrene induces larger and phenotypically different atherosclerotic plaques in ApoE-knockout mice. Am J Pathol 2004, 164(1):101-108.
27. Zhang Y., Ramos K.S. The development of abdominal aortic aneurysms in mice is enhanced by benzo(a)pyrene. Vasc Health Risk Manag 2008, 4(5):1095-1102.